A Phase 4 interventional study of cyclosporine 0.05% ophthalmic emulsion and carboxymethylcellulose-based lubricant eye drops in Dry Eye Syndromes, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-18.
Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing cyclosporine in Dry Eye Syndromes — 5 open to participants now, 5 under way, none of them phase 3. Cyclosporine · Dry Eye Syndromes.
Among the 45 studies testing cyclosporine in Dry Eye Syndromes, this one is the 26th largest by enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2014, is one of 23 in phase 4, and was the 15th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →5 of the 45 studies testing cyclosporine in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:
Ocular Aesthetics, LLC dba Ocular Clinical Trials · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 18+
The University of New South Wales · Sites in Australia
Ages 18+
Canyon City Eyecare · Sites in United States
Ages 18+
Baylor College of Medicine
Ages 18+
By country, each count listing its studies:
Cyclosporine: first FDA approval 1983 (SANDIMMUNE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 51 across the 41 interventional studies. Of the 35 that completed or were terminated, 11 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 45 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
48 studies in Dry Eye Syndromes by AbbVie: 1 open now, 1 under way, none of them phase 3. Of 47 finished, 40 (85%) have results posted.
Among the 48 studies in Dry Eye Syndromes by AbbVie, this one is the 32nd largest by enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2014, is one of 9 in phase 4, and was the 26th registered.
AbbVie’s Dry Eye Syndromes studies by the year they started, since 2001.
5 of the studies testing cyclosporine in Dry Eye Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06898853The University of New South WalesThe Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes | 2026-12-30 |
| NCT07553455Canyon City EyecareVevye + Flarex Combination Therapy for Dry Eye | 2026-12-31 |
| NCT07224529University of Alabama at BirminghamEfficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction | 2027-02-01 |
| NCT07904728Ocular Aesthetics, LLC dba Ocular Clinical TrialsTreating Contact Lens Discomfort With Cyclosporine 0.1% Ophthalmic Solution | 2027-03-15 |
| NCT07368595Baylor College of MedicineComparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks | 2027-03-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 45 studies testing cyclosporine in Dry Eye Syndromes, from their registry updates:
Among AbbVie’s 48 in Dry Eye Syndromes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and efficacy of cyclosporine 0.05% ophthalmic emulsion (Restasis®) in patients with dry eye disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily and carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
Drug: cyclosporine 0.05% ophthalmic emulsion · Drug: carboxymethylcellulose-based lubricant eye drops
Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily for 6 months.
Also known as: Restasis®
Carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
Also known as: Refresh OPTIVE® Advanced
Change From Baseline in Total Corneal Staining Score With Fluorescein in the Worse Eye
Total corneal staining with fluorescein is measured in the worse eye utilizing the Ora CalibraTM Corneal Flourescein Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).
Time frame: Baseline, Month 6
Change From Baseline in Total Conjunctival Staining Score With Fluorescein in the Worse Eye
Total conjunctival staining with fluorescein is measured in the worse eye utilizing the Ora CalibraTM Conjunctiva Flourescein Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).
Time frame: Baseline, Month 6
Change From Baseline in Total Corneal Staining Score With Lissamine Green in the Worse Eye
Total corneal staining with lissamine green is measured in the worse eye utilizing the Ora CalibraTM Corneal Lissamine Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).
Time frame: Baseline, Month 6
Change From Baseline in Total Conjunctival Staining Score With Lissamine Green in the Worse Eye
Total conjunctival staining with lissamine is measured in the worse eye utilizing the Ora CalibraTM Conjunctiva Lissamine Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).
Time frame: Baseline, Month 6
Change From Baseline in Reading on the Ocular Surface Disease Index (OSDI)
The OSDI consists of 12 questions measuring the presence of ocular symptoms. The reading question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The reading score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
Time frame: Baseline, Month 6
Change From Baseline in Driving at Night on the OSDI
The OSDI consists of 12 questions measuring the presence of ocular symptoms. The driving at night question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The driving at night score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
Time frame: Baseline, Month 6
Change From Baseline in Working With a Computer or Bank Machine on the OSDI
The OSDI consists of 12 questions measuring the presence of ocular symptoms. The working with a computer or bank machine question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The working with a computer or bank machine score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
Time frame: Baseline, Month 6
Change From Baseline in Watching TV on the OSDI
The OSDI consists of 12 questions measuring the presence of ocular symptoms. The watching TV question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The watching TV score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
Time frame: Baseline, Month 6
Change From Baseline in Reading Rate
Reading speed is assessed as the number of words read correctly in 2 minutes.
Time frame: Baseline, Month 6
Change From Baseline in Words Read Incorrectly
The numbers of words read incorrectly are counted in 2 minutes. A positive change from baseline indicates a worsening, and a negative change from baseline indicates an improvement.
Time frame: Baseline, Month 6
Change From Baseline in Font Size
The minimum font (letter) size read correctly is assessed. Smaller font size indicates better ability. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
Time frame: Baseline, Month 6
Change From Baseline in OSDI
The OSDI consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions is assessed using a 5-point scale (0=none of the time; 4=all of the time). The score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
Time frame: Baseline, Month 6
Change From Baseline in Ocular Discomfort on a 4-point Scale
Ocular discomfort is assessed on a 4-point scale where 0=no discomfort and 3=most discomfort. A positive number change from baseline indicates a worsening and a negative number change from baseline indicates an improvement.
Time frame: Baseline, Month 6
Change From Baseline in Tear Film Break-up Time in the Worse Eye
TFBUT is defined as the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A positive number change from baseline indicates improvement and a negative number change from baseline indicates a worsening.
Time frame: Baseline, Month 6
Change From Baseline in the Interblink Interval in the Worse Eye
The interblink interval measures the time (seconds) between blinks in the worse eye. A positive number change from baseline indicates a worsening (more frequent blinks) and a negative number change from baseline (less frequent blinks) indicates an improvement.
Time frame: Baseline, Month 6
Change From Baseline in Conjunctival Redness in the Worse Eye
Conjunctival redness is scored in the worse eye on a numeric analog scale ranging from 0=None to 4=Extremely Severe (0.5 increments were allowed). A positive number change from baseline indicates a worsening and a negative number change from baseline indicates an improvement.
Time frame: Baseline, Month 6
| Milestone | Cyclosporine 0.05% Ophthalmic Emulsion |
|---|---|
| Started | 40 |
| Completed | 37 |
| Not completed | 3 |
| Withdrew: Administrative reasons | 1 |
| Withdrew: Adverse event | 2 |
Total corneal staining with fluorescein is measured in the worse eye utilizing the Ora CalibraTM Corneal Flourescein Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).
| Scores on a Scale | Cyclosporine 0.05% Ophthalmic Emulsion |
|---|---|
| Baseline | 7.29 ± 1.409 |
| Change from Baseline at Month 6 (N=37) | -1.96 ± 1.677 |
Total conjunctival staining with fluorescein is measured in the worse eye utilizing the Ora CalibraTM Conjunctiva Flourescein Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).
| Scores on a Scale | Cyclosporine 0.05% Ophthalmic Emulsion |
|---|---|
| Baseline | 4.68 ± 1.035 |
| Change from Baseline at Month 6 (N=37) | 0.11 ± 1.162 |
Total corneal staining with lissamine green is measured in the worse eye utilizing the Ora CalibraTM Corneal Lissamine Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).
| Scores on a Scale | Cyclosporine 0.05% Ophthalmic Emulsion |
|---|---|
| Baseline | 4.43 ± 1.389 |
| Change from Baseline at Month 6 (N=37) | -0.93 ± 1.439 |
Total conjunctival staining with lissamine is measured in the worse eye utilizing the Ora CalibraTM Conjunctiva Lissamine Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).
| Scores on a Scale | Cyclosporine 0.05% Ophthalmic Emulsion |
|---|---|
| Baseline | 4.21 ± 1.255 |
| Change from Baseline at Month 6 (N=37) | 0.30 ± 1.356 |
The OSDI consists of 12 questions measuring the presence of ocular symptoms. The reading question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The reading score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
| Scores on a Scale | Cyclosporine 0.05% Ophthalmic Emulsion |
|---|---|
| Baseline | 1.4 ± 1.11 |
| Change from Baseline at Month 6 (N=36) | -0.7 ± 1.07 |
The OSDI consists of 12 questions measuring the presence of ocular symptoms. The driving at night question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The driving at night score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
| Scores on a Scale | Cyclosporine 0.05% Ophthalmic Emulsion |
|---|---|
| Baseline | 2.3 ± 1.46 |
| Change from Baseline at Month 6 (N=28) | -0.5 ± 1.32 |
The OSDI consists of 12 questions measuring the presence of ocular symptoms. The working with a computer or bank machine question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The working with a computer or bank machine score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
| Scores on a Scale | Cyclosporine 0.05% Ophthalmic Emulsion |
|---|---|
| Baseline | 2.2 ± 1.10 |
| Change from Baseline at Month 6 (N=34) | -1.0 ± 1.06 |
The OSDI consists of 12 questions measuring the presence of ocular symptoms. The watching TV question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The watching TV score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
| Scores on a Scale | Cyclosporine 0.05% Ophthalmic Emulsion |
|---|---|
| Baseline | 1.7 ± 1.04 |
| Change from Baseline at Month 6 (N=32) | -0.8 ± 1.04 |
Reading speed is assessed as the number of words read correctly in 2 minutes.
| Words/Minute | Cyclosporine 0.05% Ophthalmic Emulsion |
|---|---|
| Baseline | 105.2 ± 17.11 |
| Change from Baseline at Month 6 (N=37) | 3.5 ± 11.69 |
The numbers of words read incorrectly are counted in 2 minutes. A positive change from baseline indicates a worsening, and a negative change from baseline indicates an improvement.
| Words | Cyclosporine 0.05% Ophthalmic Emulsion |
|---|---|
| Baseline | 0.4 ± 0.64 |
| Change from Baseline at Month 6 (N=37) | 0.2 ± 0.90 |
The minimum font (letter) size read correctly is assessed. Smaller font size indicates better ability. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
| Size | Cyclosporine 0.05% Ophthalmic Emulsion |
|---|---|
| Baseline | 12.0 ± 0.00 |
| Change from Baseline at Month 6 (N=37) | -0.2 ± 0.75 |
The OSDI consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions is assessed using a 5-point scale (0=none of the time; 4=all of the time). The score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
| Scores on a Scale | Cyclosporine 0.05% Ophthalmic Emulsion |
|---|---|
| Baseline | 47.0 ± 16.97 |
| Change from Baseline at Month 6 (N=37) | -19.7 ± 14.43 |
Ocular discomfort is assessed on a 4-point scale where 0=no discomfort and 3=most discomfort. A positive number change from baseline indicates a worsening and a negative number change from baseline indicates an improvement.
| Scores on a Scale | Cyclosporine 0.05% Ophthalmic Emulsion |
|---|---|
| Baseline | 2.85 ± 0.921 |
| Change from Baseline at Month 6 (N=37) | -1.30 ± 1.266 |
TFBUT is defined as the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A positive number change from baseline indicates improvement and a negative number change from baseline indicates a worsening.
| Seconds | Cyclosporine 0.05% Ophthalmic Emulsion |
|---|---|
| Baseline | 1.55 ± 0.428 |
| Change from Baseline (N=37) | 0.92 ± 1.044 |
The interblink interval measures the time (seconds) between blinks in the worse eye. A positive number change from baseline indicates a worsening (more frequent blinks) and a negative number change from baseline (less frequent blinks) indicates an improvement.
| Seconds | Cyclosporine 0.05% Ophthalmic Emulsion |
|---|---|
| Baseline | 4.18 ± 3.233 |
| Change from Baseline at Month 6 (N=35) | 3.04 ± 10.637 |
Conjunctival redness is scored in the worse eye on a numeric analog scale ranging from 0=None to 4=Extremely Severe (0.5 increments were allowed). A positive number change from baseline indicates a worsening and a negative number change from baseline indicates an improvement.
| Scores on a Scale | Cyclosporine 0.05% Ophthalmic Emulsion |
|---|---|
| Baseline | 2.06 ± 0.709 |
| Change from Baseline at Month 6 (N=37) | -0.03 ± 0.707 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cyclosporine 0.05% Ophthalmic Emulsion | — | 2/40 (5%) | 12/40 (30%) |
| Event | Cyclosporine 0.05% Ophthalmic Emulsion |
|---|---|
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/40 |
| Renal Failure AcuteRenal and urinary disorders | 1/40 |
| Transient Ischaemic AttackNervous system disorders | 1/40 |
| Event | Cyclosporine 0.05% Ophthalmic Emulsion |
|---|---|
| Instillation Site BurnGeneral disorders | 3/40 |
| Instillation Site PainGeneral disorders | 3/40 |
| Eye IrritationEye disorders | 2/40 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/40 |
| HeadacheNervous system disorders | 2/40 |
| Age, Continuous(Years) | Cyclosporine 0.05% Ophthalmic Emulsion |
|---|---|
| Mean | 59.4 ± 9.05 |
| Sex: Female, Male(Participants) | Cyclosporine 0.05% Ophthalmic Emulsion |
|---|---|
| Female | 35 |
| Male | 5 |
Ran from Apr 2014 to primary completion in Sep 2014, 5 months.
Results were first posted in Apr 2016, 1 year 7 months after primary completion.
Of 28 industry-sponsored phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 15. This study's 5 months is below that.
Counting every sponsor, half of 112 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclosporine